Evidence map›Paper›PMID 35217670›Full record

Trial reportNature communications2022

Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases.

Pierre H H Schneeberger, Morgan Gueuning, Sophie Welsche, Eveline Hürlimann, Julian Dommann, Cécile Häberli, Jürg E Frey, Somphou Sayasone, Jennifer Keiser

Open access · goldAbstract readRandomized Controlled TrialClinical Trial, Phase IIClinical Trial, Phase III
In one paragraph

Trial report in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Distinct gut microbiome features characterizeFrontiers in cellular and infection microbiology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Regulation Effect ofMicroorganisms · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Impact of Ivermectin on the Gut Microbial Ecosystem.International journal of molecular sciences · 2023
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Pierre H H SchneebergerSwiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, Helminth Drug Development Unit, Basel, Switzerland. pierre.schneeberger@swisstph.ch.ORCID http://orcid.org/0000-0002-8586-4937
Morgan GueuningAgroscope, Research Group Molecular Diagnostics, Genomics and Bioinformatics, Wädenswil, Switzerland.
Sophie WelscheSwiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, Helminth Drug Development Unit, Basel, Switzerland.
Eveline HürlimannSwiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, Helminth Drug Development Unit, Basel, Switzerland.
Julian DommannSwiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, Helminth Drug Development Unit, Basel, Switzerland.
Cécile HäberliSwiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, Helminth Drug Development Unit, Basel, Switzerland.
Jürg E FreyAgroscope, Research Group Molecular Diagnostics, Genomics and Bioinformatics, Wädenswil, Switzerland.
Somphou SayasoneUniversity of Basel, Basel, Switzerland.
Jennifer KeiserSwiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, Helminth Drug Development Unit, Basel, Switzerland. jennifer.keiser@swisstph.ch.ORCID http://orcid.org/0000-0003-0290-3521
Swiss Tropical and Public Health Institute · CHAgroscope · CHUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soil-transmitted helminth infections represent a large burden with over a quarter of the world's population at risk. Low cure rates are observed with standard of care (albendazole); therefore, a more effective combination therapy (albendazole and ivermectin) is being investigated but showed variable treatment efficacies without evidence of intrinsic parasite resistance. Here, we analyzed the microbiome of Trichuris trichiura and hookworm-infected patients and found an association of different enterotypes with treatment efficacy. 80 T. trichiura-infected patients with hookworm co-infections from Pak-Khan, Laos, received either albendazole (n = 41) or albendazole and ivermectin combination therapy (n = 39). Pre-/post-treatment stool samples were collected to monitor treatment efficacy and microbial communities were profiled using 16S rRNA gene sequencing, qPCR, and shotgun sequencing. We identified three bacterial enterotypes and show that pre-treatment enterotype is associated with efficacy of the combination treatment for both T. trichiura (CR

Indexed as

AnthelminticsHelminthiasisMicrobiotaTrichuriasisAlbendazoleFecesHumansIvermectinParasite Egg CountRNA, Ribosomal, 16SSoilAlbendazoleAnthelminticsIvermectinRNA, Ribosomal, 16SSoil

Identifiers

PMID35217670
PMCPMC8881608
OpenAlexW4214561734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.